Qure.ai Announces Appointment of Amit Kakar and Charles-Antoine Janssen to its Board of Directors

  • The company has also added Navjeewan Khosla from Novo Holdings and Ajay Mahipal from HealthQuad as Board Observers 


    Novo Holdings and HealthQuad had led Qure.ai’s Series C funding for $40 Million in March 2022 


Qure.ai, one of the leading health tech firms using Artificial Intelligence (AI) for medical imaging diagnostics, has announced the appointment of two new members to its Board of Directors. Joining the team at the helm are Dr. Amit Kakar MD, from Novo Holdings and Mr. Charles-Antoine Janssen, Chief Investment Officer, HealthQuad. The announcement comes on the heels of Qure.ai’s $40 million funding round led by Novo Holding and HealthQuad in March 2022. They have also appointed Mr. Navjeewan Khosla, Principal, Novo Holdings and Mr. Ajay MahipalMahipal, Director, HealthQuad, as Board Observers.  


Dr. Amit Kakar is Senior Partner, Head of Novo Holdings Asia, and a healthcare professional with over 30 years of experience across key verticals including Medical Technology, R&D, Manufacturing, Pharma Retail, Drug Discovery, Clinical Research, Biotech, Hospitals and Diagnostic Centers, Primary and Specialty Care Centers, among others. His diverse experience also encompasses investing, operational and management roles across health-tech companies. He is currently part of the Board of Directors of Singapore-based life science company, ESCO, and telemedicine portal – Doctor Anywhere. As a senior partner, Dr. Kakar’s invaluable expertise can help Qure scale global markets. 


Novo Holdings is a world-leading healthcare and life sciences investor with a focus on creating long-term, sustainable value. Headquartered in Copenhagen, Denmark, with offices in San Francisco, Boston, London and Singapore, Novo Holdings has a portfolio of more than 150 companies.  


Dr. Amit Kakar, Senior Partner, Head of Novo Holdings Asia said, “I am passionate about diagnostic imaging which is being transformed by machine learning and real-world data. Qure is in the forefront of that change in providing affordable and accessible healthcare to patients across the globe. I am looking forward to working closely with the team and my fellow board members on this next exciting phase of Qure.ai’s journey.”  


Commenting on the occasion, Navjeewan Khosla , Principal, Novo Holdings said that; “We are very excited to partner with Prashant and his team at Qure.ai. Healthcare innovation, especially for developing economies, is a critical aspect that can help rewrite the current narrative. With technological intervention and intelligent solutions, we believe that quality healthcare can be made acessible and affordable to all. Qure.ai’s vision for its future is in perfect agreement with that and I look forward to working together to achieve new heights of success for all of us.” 



Charles-Antoine Janssen is the Chief Investment Officer at HealthQuad and the Co-Founder & Managing Partner at KOIS S.A., a global impact investing firm. HealthQuad is a joint venture between KOIS S.A. and Quadria Capital, with an exclusive focus on the Indian health-tech market. Charles-Antoine has over 26 years of industry experience and is a well-versed impact investor focused on healthcare access. His vision to nurture innovative models that can transform healthcare, is in perfect alignment with Qure’s vision to use AI and make quality healthcare accessible to all. Charles-Antoine serves on the board of Medikabazaar, THB, Lilac Insights, TC4AI, Regency Hospitals, GoJob, the Climate School and Potential Project, and on the Advisory Board of Lighthouse (India PE fund) and Quadria (Asia healthcare PE fund). He is also a member of the board and audit committee of UCB, as well as a board member of Tubize (UCB’s listed reference shareholder). 


HealthQuad is India’s leading digital health-focused venture capital fund, with assets under management of USD 200 Mn across two funds. Its focus is to nurture innovative models which radically improve healthcare access and affordability by leveraging technology. 


Charles-Antoine Janssen, Chief Investment Officer, HealthQuad said; “India’s healthcare market is at an inflection point, with digital healthcare solutions front-ending the disruption. Technology-led healthcare is the most promising sunrise sector in the country, forecasted to race ahead at a CAGR of 26 per cent to $21bn by 2025. We are focused on partnering with innovators who can help bridge gaps in the access to quality healthcare for rural and semi-urban communities without adding to their financial burden. Qure.ai is an ideal springboard to take our vision to the next level with their AI-powered imaging technologies, that impact 4 mn lives annually and are deployed across the public health spectrum in 50+ countries. I am looking forward to being part of Qure’s next phase of growth to make quality healthcare an affordable reality for all.” 


Commenting on his new position as Board Observer, Ajay Mahipal, Director, HealthQuad said that; It is the need of the hour to foster innovations that can radically change the means in which quality healthcare is made accessible to all. We at HealthQuad are particular to partner with companies and innovators who are making a difference and we could not be happier to welcome Qure.ai to our midst. I am elated to be part of Qure, a company that has been continuously scaling up and addressing the accessibility and affordability quotient for healthcare through its innovative products. It will be an honor to be part of the esteemed board of directors and weigh in on Qure’s global growth roadmap.” 


Qure.ai is poised for accelerated global growth and foray into new markets. The new members of the board will be crucial in guiding the organization in scaling up aggressively. They will also be instrumental in extending and strengthening Qure.ai's global reach, especially in the US and European markets, and intensifying product development for critical care and community diagnostics.    


Commenting on the new appointments, Prashant Warier, CEO and Founder, Qure.ai said that “We are delighted to welcome Dr Amit and Mr. Charles-Antoine to our esteemed board of directors. We are equally elated to have Mr. Navjeevan Khosla and Mr. Ajay Mahipal join us with their unique perspectives, stemming from their extensive experience in the healthcare industry. They have joined us at a key/crucial juncture in our company’s growth. We strongly believe that their collective experience in leading global health-tech companies will be a great advantage to Qure, as we gear up for massive global growth. We are excited to have newer perspectives added to our board of directors and is looking forward to making quality healthcare accessible to all.” 


Dr. Amit Kakar and Charles-Antoine Janssen join Anandamoy Roychowdhary of Sequoia India, Ryan Collins of MassMutual Ventures, and Srikanth Velamakanni, and Satish Raman from Fractal Analytics Private Limited alongside Prashant Warier, CEO and Founder, Qure.ai. The new appointments are effective immediately.  


USAID-supported SAMRIDH Healthcare Blended Finance Facility supports Qure.ai to strengthen India’s healthcare systems

The financial assistance will help Qure.ai expand its artificial intelligence solution to screen for lung diseases across 15 states in India

The SAMRIDH Healthcare Blended Financing Facility, supported by the U.S. Agency for International Development (USAID) and implemented by IPE Global, has committed 2.45 Crore INR ($350,000 USD) to Qure.ai to scale Artificial Intelligence (AI)-enabled chest X-ray screening software, qXR, in 50 sites across more than 15 Indian states. The software will enable healthcare workers in the dual screening of COVID-19 and lung diseases such as Tuberculosis, in remote and resource-challenged locations, and will benefit an estimated 62,500 people in the next 12-14 months.

Qure.ai is a leading health-tech firm that builds AI-powered solutions focusing on pulmonary and neurocritical care to deliver better patient outcomes. Qure.ai’s CE-approved qXR software not only detects 30 critical lung abnormalities in under a minute but can also quantify the infection, giving healthcare workers real-time insights into disease progression. As a result, it provides instant diagnostic support and actionable insights for frontline healthcare workers while optimizing resources and strengthening community care.

The USAID-supported SAMRIDH Blended Finance Facility, through partnerships with organizations including Qure.ai, aims to advance its mission to scale market-based solutions and build sustainable and resilient healthcare systems for India. SAMRIDH offers both grant and debt financing provision to healthcare enterprises and innovators to improve their capacity for production and supply of high-impact health solutions that can be scaled rapidly to meet health challenges posed by the pandemic and future crises. This is complemented with a strong technical assistance and capacity building component, enabling enterprises to unlock new sources of capital through blended financing solutions, while ensuring long-term sustainability and expansion.

Speaking about this partnership, Mr. Himanshu Sikka, Project Director, SAMRIDH said, “We welcome the opportunity to support Qure.ai in expanding its AI-led solution to detect COVID-19 and lung diseases. It is faster, accurate, cost-effective, and will truly transform diagnostics in primary healthcare settings. Through this collaboration, we reinforce our commitment to drive greater investments in market solutions that combine technology and innovation to improve access to quality and affordable healthcare services for vulnerable populations.”


Prashant Warier, CEO and Founder of Qure.ai said, “We are pleased to receive this support from USAID and IPE Global Limited. Our AI technology for chest X-ray screening and interpretation can better the lives of patients and medical personnel. Remote locations in India struggle for resources to deal with highly transmissible infectious diseases like Tuberculosis and COVID-19. Our AI solution will significantly improve diagnosis, treatment, and patient health. I believe it can pave the way for the deployment of advanced healthcare solutions in more public health settings.”

Qure.ai raises $40 Million from healthcare investors Novo Holdings and HealthQuad

The funding will accelerate the AI-driven healthcare company’s market expansion into the global market and support new product development   

We are happy to announce that we have secured $40 million in a funding round led by Novo Holdings and HealthQuad, supported by existing investor Mass Mutual Ventures. We will use the new investment to extend and strengthen our global reach, especially in the US and Europe, and intensify product development for critical care and community diagnostics.

We have created a niche for ourselves with advanced technology that reads and interprets medical images like X-rays, CTs, and Ultrasounds in less than a minute, making equitable and high-quality healthcare a reality across the globe. Our AI solutions are FDAapproved, CEcertified, and evaluated by the World Health Organization.

Our automated medical imaging tools can shorten the time to diagnosis while enabling physicians to triage medical cases more effectively, especially in time-sensitive situations. This helps healthcare providers identify critical scenarios within minutes — versus hours — to avert fatalities and improve the quality of patient care. In other settings, where adequate, skilled specialists may not be available, our technology is used as the first level of screening for many infections and non-communicable

Dr. Amit Kakar, Senior Partner, Head of Novo Holdings Equity Asia, said: “We are very pleased to join the outstanding team at Qure.ai and to contribute to their efforts of providing world-class AI solutions in the imaging space, for the benefit of patients worldwide. Qure.ai is at the forefront of transforming diagnostics in both acute and chronic ailments, which is fully aligned with our mission of advancing high-quality and accessible healthcare using innovation and digitization. Further, we are excited to connect Qure.ai to our portfolio partners as we see several promising synergies.”

Novo Holdings is a worldleading healthcare and life sciences investor with a focus on creating long-term, sustainable value. Headquartered in Copenhagen, with offices in San Francisco, Boston, London, and Singapore, Novo Holdings has a portfolio of more than 150 companies.  

Charles – Antoine Janssen, Chief Investment Officer, HealthQuad said: “We are thrilled to be part of the Qure team. Their world-class AI technologies adhere to the most stringent international standards, and have made high-quality, accessible care a reality. We remain committed to collaborating with innovative firms that work to improve global healthcare infrastructures." 

“It’s no accident that Qure is one of the leading startups thriving in the health tech sector. Through noteworthy collaborations with ministries of health and government entities like the NHS, pharmaceuticals like AstraZeneca, and international advocacy groups like StopTB, amongst others, Qure has already built a network of global commercial partnerships. The pandemic has also accelerated the shift to digital transformation, and we are proud to back their growth,added Ajay Mahipal, Director, HealthQuad.  

HealthQuad is India’s leading digital health-focused venture capital fund with assets under management of USD 200 Mn across two funds. Its focus is to nurture innovative models which radically improve healthcare access and affordability by leveraging technology.

Prashant Warier, CEO and Founder, Qure.ai, said: “Every year our technology helps more than four million people across 50 countries. Our goal is to continue being bullish in our market expansion, especially in the US and Europe. We are committed to aiding healthcare professionals in diagnosing illnesses faster and with more detail and accuracy while automating most of the routine work. This is a win for all involved in healthcare, especially for patients across the globe who will benefit from vastly improved health outcomes.

Ryan Collins, Managing Director, MassMutual Ventures said: “We have been incredibly impressed with Qure’s progress since we first invested over two years ago. The team is exceptional and the progress on product development, now across many different imaging modalities and use cases, as well as global expansion, has been outstanding. We are very happy to continue supporting Qure and welcome Novo and HealthQuad as partners.”  

SBRI Healthcare announces £3.2 million in Funding for Qure.ai’s AI Technology for Cancer Detection

Award part of £9 million programme for late-stage innovation projects that advance the earlier and faster diagnosis of cancer 

London, February 8th 2022: Today, SBRI Healthcare, in partnership with the NHS Cancer Programme and the Accelerated Access Collaborative, announced that Qure.ai has secured £3.2 million in funding for late-stage innovation projects that aid in the earlier and faster diagnosis of cancer. This funding announcement follows recent comments from Sajid Javid, the Health and Social Care Secretary, where he declared “a national war on cancer” as the UK seeks to develop a new 10-year plan for cancer treatment.

With this SBRI funding, Qure.ai will demonstrate real-world evidence of AI-aided diagnosis of lung cancer based on triage of suspected lung nodules on chest X-rays and immediate reporting of the same for prompt follow through and confirmation. This will also lead to faster chest computed tomography (CT) scans for suspected cases and eventually impact early-stage lung cancer detection. Clinical and cost-effectiveness data will be used in a thorough prospective evaluation to establish clinical relevance before moving to wider adoption.

The project brings in lung cancer expertise under the clinical leadership of Prof David Baldwin, Chair, UK Clinical Expert Group for Lung Cancer, Dr Richard Lee, National Institute for Health Research Specialty Lead Screening, Prevention and Early Detection, Dr Neal Navani, Senior Clinical Lead of the UK National Lung Cancer Audit and Dr Nick Woznitza MBE, Consultant Radiographer from University College London Hospital NHS Trust and Canterbury Christ Church University.  

Prof Baldwin said “Speed of diagnosis is critical to achieve the best outcomes in lung cancer and to reduce stress and worry for patients. AI solutions such as qXR should improve the pathway logistics by flagging abnormalities on chest x-rays as soon as they are undertaken helping patients to progress rapidly through to CT scanning. This will also assist our incredibly busy workforce. This exciting study will show us just how useful a well-validated AI solution is in our NHS.”

Dr Richard Lee commented, “Lung cancer is the most common cause of cancer deaths worldwide. It is vital that we make every attempt to diagnose cancer earlier since treatment is much more effective and many more patients live longer, healthier lives if we can use more curative treatments in those diagnosed earlier. The SBRI funded collaboration with Qure.ai and other respiratory colleagues across the UK is an immensely valuable opportunity to demonstrate how artificial intelligence tools can lead to earlier lung cancer diagnosis and improve patient outcomes. Such techniques can sit alongside our other liquid biopsy research to improve cancer survival in a multi-pronged approach and ensure that those patients in whom we cannot detect lung cancer by screening in targeted lung health checks, can still benefit from the very latest innovations."

“We know that early, accurate and rapid diagnosis of lung cancer is critical if we are to improve outcomes for patients. With the number of chest X-rays performed each year in the NHS we need to evaluate how we can identify priority cases and this large-scale prospective study will provide robust clinical and health economic evidence on the role of AI in lung cancer imaging,” added Dr Nick Woznitza.

Qure would be collaborating with leading NHS Trusts in the UK that have a focus on lung cancer including the Nottingham University Hospital Trust, The Royal Marsden NHS Trust, University College London Hospital NHS Trust, University Hospitals Birmingham NHS Trust, and several other regional NHS Trusts.

“Lung cancer is the leading cause of cancer-related deaths in the United Kingdom. Although 5-year survival rates have improved recently, they remain low at roughly 14%, with 30% of patients dying within 90 days after diagnosis” said Prashant Warier, CEO and founder, Qure.ai. “We support the Health and Social Care Secretary’s vision to fight cancer because we are optimistic that artificial intelligence (AI) can play a vital role in early identification of lesions which can lead to faster diagnosis through same-day CT scans. This initiative will look to demonstrate that it is possible to impact every step of the lung cancer diagnosis process through AI and assist in delivering better outcomes for patients.”

Qure.ai’s qXR is a CE-approved chest X-ray interpretation AI solution built using millions of images and deep learning. It classifies chest X-rays as normal or abnormal, identifies abnormal findings, and highlights them on the X-ray. It can detect and localize multiple findings in a chest X-ray including detection of multiple findings with the lungs, pleura, heart, bones, and diaphragm. The qXR algorithm detects lung nodules and assigns them a lung malignancy-risk score, reducing the chances of missed diagnosis. It is one of the most deployed AI solutions, with multiple peer-reviewed publications and clinical users in 40+ countries.

This competition marks the beginning of an anticipated annual series of multi-million-pound funding opportunities in support of the LTP cancer ambitions. Launched in March 2021, it is the first of its kind, and attracted 51 applications from the open market. It called for late-stage solutions to the challenges of improving the early detection and diagnosis of cancer; and diagnostic efficiency for cancer services. All winning technologies have already proven their clinical effectiveness, and through this programme, will be implemented either locally or nationally to prove they can be rolled out nationwide within the NHS.

Qure.ai’s breathing tube placement AI technology receives FDA clearance

The algorithm improves critical care management for improper tube placements

New York, 20th Jan 2022: Leading health tech firm Qure.ai has gained 510(k) clearance from the Food and Drug Administration (FDA) for an artificial intelligence (AI) algorithm called qXR-BT, that will help doctors in assessing Breathing Tube (BT) placements. Through chest X-rays, the algorithm assists clinicians for intubated patients in locating the BT placement and automating measurements. This is the first solution of its kind to automate the manual measurement process for both endotracheal and tracheostomy tubes.

Verification of endotracheal tube (ETT) placement is imperative for the oxygenation, ventilation, and airway protection of your patient. While a common procedure done in hospitals daily, Rates for incorrect ET tube placement have been noted to be up to 25%. According to the Society of Airway Management, mistakes during the intubation process threaten the lives of 121,000 hospital intensive care unit patients annually in the United States. Even if you have an expert clinical team inserting and securing the tube after the initial placement, ETT migration is an inevitable consequence of coughing, suctioning, transport, and patient movement.

Qure's qXT-BT algorithm analyzes the tube position, automates measurement, and gives the physician a report on the tube’s positional accuracy in less than a minute. This enables clinicians to rapidly identify if the tube is properly positioned or whether extra attention is required. The algorithm is vendor-agnostic and is designed to work on both portable and stationary X-ray machines.

Dr. Mannudeep Kalra, attending thoracic radiologist, Massachusetts General Hospital and Professor of Radiology, Harvard Medical School, who was involved in a research collaboration evaluating the technology said, “Daily monitoring of Tubes is critical for all intubated inpatients, and sometimes an arduous task on the portable exam with either the carina obscured or the tip not visible. An accurate AI solution could be a valuable aid for reporting on these chest X-rays- especially with the measurement.”

“We are pleased to have received FDA clearance for qXR-BT. In the last two years, we have seen the need to decrease processing times and solve workflow delays,” said Prashant Warier, CEO and Co-Founder, Qure.ai. “Especially in the wake of the COVID-19 pandemic and the need for mechanical ventilation in affected patients, the need for prompt assistance to an overburdened healthcare workforce is paramount,” he added.

qXR-BT is expected to become a standard feature of any critical care framework, giving residents and
junior clinicians more confidence in reliably measuring breathing tube placement in intubated patients.

Qure.ai bags second FDA clearance for Brain CT scan AI

qER-Quant will help enable faster diagnosis and help track patient progression over time

New York, 17th Aug 2021: Leading medical image AI provider Qure.ai has announced US FDA 510(k) clearance for its brain CT quantification product qER-Quant. Clinicians in the US can now use this tool to rapidly and precisely assess the severity of injury in patients with conditions like traumatic brain injury, hemorrhagic stroke, and hydrocephalus and to track the progression of pathology over time.

CT scans are the most widely used exam for brain injuries and are used to help diagnose millions of patients that visit the emergency room every year. AI assistance speeds up treatment and transfer decisions, helps monitor patients more closely and reduces the chances of diagnostic errors.

Ajith Thomas MD, Associate Professor of Neurosurgery, Harvard Medical School and Co-Director, Brain Aneurysm Institute, Beth Israel Deaconess Medical Center said, “The use of AI will be transformative in the management of traumatic brain injury by obtaining an expedient and accurate diagnosis. Congratulations to Qure.ai for being at the forefront of this paradigm shift!”

“Qure.ai’s technology makes it possible to systematically measure brain hemorrhages precisely and rapidly in patients with stroke or trauma. Fully automated quantification could soon become the standard of care.” says Dr Johan Wasselius, Interventional Neuroradiologist at the Skåne University Hospital and Lund University, Sweden.

“This FDA clearance adds quantification, outlining and measurement capabilities to Qure.ai’s first clearance for triage and notification of critical brain abnormalities. We are excited about bringing a complete suite of capabilities to clinicians who deal with critical head CT scans.” said Dr. Pooja Rao, Co-Founder and R&D head, Qure.ai.

“We’ve always built products to solve real customer challenges and qER Quant is another example of the same. We worked on this capability based on customer feedback from radiologists, neurologists, and ER physicians who expressed the need to get automated volume measurements on neuro scans to assess patient progress as well as safe discharge decisions. It helps us offer a more comprehensive suite of AI tools to our US clinical partners.” said Prashant Warier, CEO and co-founder, Qure.ai.

The FDA clearance and a summary of the performance of the software is available at this link. The AI tool is also cleared for marketing in the EU, and is currently used by teleradiology providers, emergency care physicians and radiologists at more than 40 clinical sites, helping process thousands of scans every day.

Qure.ai partners with Healthcare Imaging Services to bring Artificial Intelligence to chest X-ray diagnosis in Australia

16th July 2021, Sydney – Qure.ai leaders in developing deep learning algorithms for interpreting radiology images, is excited to announce a strategic partnership with Healthcare Imaging Services (HIS), the diagnostic imaging provider in the Healius Group.

The collaboration will see HIS integrating Qure’s artificial intelligence (AI) solutions to aid chest X-ray interpretation.

HIS has one of the largest networks of imaging centres in Australia and focuses on supplying high quality and comprehensive imaging diagnosis, annually processing close to three million scans. By using an automated X-ray screening technology called qXR from Qure, they will elevate patient care by aiding radiologists to prioritise critical cases, detect incidental findings and lower the chances of misdiagnosis.

The qXR AI algorithm can detect 30 distinct radiological abnormalities from chest X-rays, including lung opacities, nodules, cardiomegaly and pleural effusion. The first AI solution to be CE certified, qXR is now listed as a medical device on the Australian Register of Therapeutic Goods and has a sensitivity of over 95 per cent. Radiologists can use qXR as a pre-assistance read to separate normal from abnormal X-rays, making sure they get to the critical cases earlier.

Prashant Warier, CEO and co-founder of Qure.ai said, “Partnering with Healthcare Imaging Services is a significant milestone in making a positive contribution to Australia’s healthcare system. We are excited about how our AI technology for chest X-ray screening and interpretation can better the lives of both patients and medical personnel. Early disease detection has always been a critical factor in meticulous treatment, and better clinical outcomes for patients and our AI solution is geared to provide support to Australia’s doctors in both speed and accuracy of diagnoses.”

Dean Lewsam, CEO of Healthcare Imaging Services, is very excited about this collaboration: “This partnership is something as a business we are very excited about. We want to provide faster, more accurate care to our patients and the collaboration between our people across the country and qXR AI algorithm will allow us to do that.”

Qure.ai’s Brain CT AI wins funding from the NHS

The grant will help Qure.ai combine the power of artificial intelligence with the expertise of the NHS to improve patient outcomes

London, 16th June 2021 – Today, the UK Department of Health and Social Care announced that Qure.ai has been selected as one of the winners of the Artificial Intelligence in Health and Care Award, sponsored by the UK government. Qure.ai is a 5-year-old Sequoia-funded company builds Artificial Intelligence (AI) powered solutions to facilitate identification and treatment of stroke and head injuries. The Award has been instituted by the Accelerated Access Collaborative (AAC) in partnership with NHSX and the National Institute for Health Research (NIHR). The consortium is making £140 million available over four years in funding and support for promising AI technologies.

The award will drive Qure.ai’s mission to gather real-world evidence for its qER tool in an ER setting, in partnership with the NHS Guy’s and St. Thomas’ Foundation Trust, NHS King’s College Hospital Foundation Trust, NHS Northumbria Healthcare Foundation Trust and other key Major Trauma focused NHS trusts across the country.

qER is Qure.ai’s AI platform that identifies a range of critical abnormalities on head CT scans, such as bleeds, strokes and fractures. The technology is CE-marked and received United States FDA clearance in 2020. qER will now be deployed in Accident and Emergency (A&E) departments in the UK to improve diagnostic turn-around times for these critical conditions and help reduce missed diagnoses.

The NHS has seen a significant rise in A&E footfalls as well as growing volumes and complexity of imaging, with CT and MRI volumes increasing by an average of 10% (over half a million scans) per year, while patient wait times in the A&E have been steadily increasing too. For better patient outcomes, the time to diagnosis and treatment is critical, particularly for patients with neuro presentations such as head trauma or stroke.

Dr. Haris Shuaib, Consultant Physicist, Head of Clinical Scientific Computing at Guy’s and St Thomas’ NHS Foundation Trust said, “Our out-of-hours radiology reporting service would benefit greatly from an effective triaging and prioritisation system. With the qER system from Qure we hope to be able to manage critical findings like intracranial hemorrhage even more effectively.”

Dr Hugh Harvey, Managing Director, Hardian Health- “Winning a Phase 3 AAC award is a testimony to the strong consortium that has come together to support deployment and scaling of Qure’s market-leading qER software. Hardian Health is truly excited to be part of this fantastic consortium. We will be conducting cost-effectiveness analysis of the care pathways by involving all stakeholders, from NHS clinicians to patient advocacy groups”.

“We are excited about this Award from NHSX”, says Dr. Pooja Rao, R&D Head and co-founder of Qure.ai. “This NHSX grant will help us demonstrate that appropriate use of AI technology leads to better patient outcomes and accrues economic benefits to the NHS system. It paves the way for wider adoption of Qure’s technology in the UK”.

Qure.ai partners with the NGO PATH to accelerate and intensify COVID-19 screening

Qure’s AI technology now available on Telegram App for clinicians for instant chest X-ray interpretation

20th May 2021, Mumbai – India’s leading health-tech startup has collaborated with the international NGO PATH, to accelerate and intensify COVID-19 screening by making advanced AI diagnostic technology available to physicians across India through the Telegram App.

Qure’s CE-certified AI solution can read and interpret chest X-ray to detect findings indicative of COVID-19 as well as quantify the proportion of lungs affected due to the lesions. The technology which is being used by the Mumbai Municipal corporation and super-specialty hospitals across the globe, is now available to physicians on the Telegram app.

The second wave in India has led to a sharp scarcity of RT-PCR tests, as well as delayed reporting and lower accuracy in the test’s results. Qure’s AI solution can help as a preliminary screening mechanism. Chest X-rays are being increasingly preferred to assess and quantify the infection in the lungs as they are more easily available, inexpensive and inflict lower radiation levels. Qure’s AI bot would enable clinicians to triage for COVID-19 instantaneously. Physicians would only have to download the Qure bot from the Telegram app, upload the patient’s chest X-rays either as DICOMs images or as images taken by the smartphone camera. The result would be available in less than a minute and would serve as a second opinion or confirmation of diagnosis.

PATH is an international NGO which has been on the forefront of enabling digital transformation in India. Working with various state governments, they have a strong history of improving the effectiveness of health programs in 22+ states through their network of physicians and healthcare workers.

Prashant Warier, CEO and co-founder of Qure.ai said “What we’ve been seeing in the last few weeks is truly taking a toll on our frontline care givers and straining our public and private healthcare infrastructure severely. We need to implement and leverage technology that’s been extensively trained and validated to tackle this ongoing tragedy fast and it needs to be now.”

Dr. Shibu Vijayan, Global TB Technical Director, PATH said “Qure’s technology detects ground-glass opacities and consolidation, which are indicative of COVID-19 infections. It quantifies affected lung volume and gives a COVID-19 score which will help physicians decide on the course of treatment. It will also help healthcare institutions with optimizing their resource allocation.”

Fujifilm partners with Qure.ai to make intelligent X-ray solutions

Artificial Intelligence technology layer provides medics with diagnostic assistance by automaticallyinterpreting X-rays in a few seconds.

19th May, Mumbai: Fujifilm India Pvt. Ltd. is pleased to announce that FUJIFILM Corporation has introduced X-ray solutions augmented with qXR, Qure.ai’s computed aided radiology software application designed with deep-learning Artificial Intelligence (AI) technology. According to Qure.ai, the AI will analyze X-ray images to detect abnormal findings within seconds. Fujifilm’s portable X-ray FDR Xair system are equipped with a new image processing box called Expansion Unit EX-Mobile enabling to connect with qXR software. It will assist clinicians and technicians by flagging abnormal findings atthe point-of-care.

Qure’s peer-reviewed and proven chest X-ray interpretation technology, qXR can detect suspected abnormalities indicative of COVID-19, tuberculosis, lung cancer, misplaced catheters and multiple other radiological findings allowing for further review and confirmatory testing. The technology has been extensively trained on a global dataset and can be used for both adult as well as pediatric images.

Another significant advancement is that the combination of EX-Mobile with Fujifilm’s portable X-ray FDR Xair system
will bring the benefit of Qure’s AI technology not only to hospitals, but also regions which are geographically distant from the cities and emergency critical care. Furthermore, it will respond to the rapidly increasing global demand for support for effective lung procedures at medical sites, especially during the disease outbreaks.

“Fujifilm and Qure’s technology will deliver a support tool to assist the care providers for accurate diagnosis faster. With the help of Technology and special examination we can diagnose the disease while it is asymptomatic, with no signs or symptoms. The earlier detection of disease may lead to more cures or longer survival. Our partnership with Qure will support the expansion of Tuberculosis(TB) screening in India, and also other developing countries where there is limited access to such health service. We believe there’s tremendous potential in this partnership” said Koji Wada, General Manager, Fujifilm India Medical Division.”

“We are delighted to partner with Fujifilm to improve quality of care by accelerating patient triage, diagnostics and treatment. Qure.ai’s CE- certified and WHO endorsed technology will elevate patient care and reduce radiologists’ workload across healthcare institutions.” said Prashant Warier, CEO and Co-Founder, Qure.ai.

Fujifilm customers will be able to select one of the clinical packages available with qXR including:

  • qXR-COVID-19 which helps to monitor change of lung density.
  • qXR-Lung Nodule that enables early detection of metastatic lung cancer by automated pulmonary nodule detection.
  • qXR-TB helps reduce the waiting time for confirmatory tests for diseases like Tuberculosis.
  • qXR-Critical Care can detect misplaced catheters and tubes which are commonly used in critical care settings for monitoring body functions and administering medications.

Fujifilm and Qure aims provide high quality care in the increasingly dynamic and complex healthcare environment through future-proof AI technology.

1. Available in select CE Mark countries. Not available in all regions.

2. EX-Mobile is option product of Fujifilm’s FDR D-EVO II DR cassette.